Skip to main content

Table 1 Characteristics of the early symptoms in rheumatoid arthritis patients with and without anti-cyclic-citrullinated peptide (anti-CCP) antibodies

From: Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis

  Anti-CCP-negative (n = 228) Anti-CCP-positive (n = 226)
Female [n (%)] 147 (64%) 150 (66%)
Age at inclusion (mean ± standard deviation) 57 ± 17 55 ± 16
Morning stiffness   
   No [n (%)] 30 (13%) 30 (13%)
   Yes (min) (mean ± standard deviation) 118 ± 138 123 ± 128
Type of initial joint symptoms [n (%)]a   
   Pain 208 (91%) 205 (91%)
   Swelling 146 (64%) 135 (60%)
   Stiffness 106 (46%) 85 (38%)
   Function loss 64 (28%) 57 (25%)
   Redness or increased surface temperature of joints 19 (8%) 26 (12%)
Localization of initial joint symptoms [n (%)]   
   Small joints of hands and/or feet 105 (46%) 112 (50%)
   Large joints 54 (24%) 50 (22%)
   Both small and large joints 63 (28%) 59 (26%)
   Unknown 6 (2%) 5 (2%)
Localization of initial joint symptoms [n (%)]   
   Upper limbs 114 (50%) 86 (38%)*
   Lower limbs 72 (32%) 77 (34%)
   Both upper and lower limbs 25 (11%) 45 (20%)*
   Unknown 18 (8%) 18 (8%)
Localization of initial joint symptoms [n (%)]   
   Symmetric 145 (64%) 130 (58%)
   Asymmetric 71 (31%) 83 (37%)
   Unknown 10 (4%) 13 (6%)
VAS patients' rated global disease activity (0–100) 51.3 ± 39.9 46.7 ± 28.2
HAQ score (mean ± standard deviation) 1.0 ± 0.7 1.0 ± 0.7
  1. VAS, visual analogue scale. HAQ, Health Assessment Questionnaire.
  2. aPatients can have both swelling and pain at the start of the symptoms and therefore the total can add to more than 100%.
  3. * P < 0.05, anti-CCP-positive versus anti-CCP-negative.